Close

Welcome back to Stockhouse
Member Sign In

Email or Username:
Password:
Close

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History  |  Analysts  |  Earnings  |  Insiders

Nuvo Research Inc T.NRI

Sector: Healthcare | Sub-Sector: Drug Manufacturers - Specialty & Generic
Alternate Symbol(s):  NRIFF | NRIFD

Nuvo Research, Inc. is a Canadian specialty pharmaceutical company with manufacturing operations. The Company operates two distinct business units: the Topical Products and Technology (TPT) Group (formerly the Pain Group) and the Immunology Group.
Price: $6.85 | Change: $-0.06 | %Change: -0.87%
Volume: 26,514 | Day High/Low: 6.94/6.80 | 52 Week High/Low: 8.33/1.93
View modes: 
5 stars

RE:One man's opinion....

Sorry guys....Need 2 already posted that....my bad  rate and reply
1 star

One man's opinion....

STOCK PICK Normally, I steer clear of biotechs. Here's why I like Nuvo Research FABRICE TAYLOR SPECIAL TO THE GLOBE AND MAIL Last updated Wednesday, Nov. 12 2014, 7:31 PM EST Nuvo Research's...read more
5 stars

Pennsaid2 and Voltaren Gel

They are the same NSAID drug called diclophenac sodium. Voltaren gel has 1.16% diclophenac and is rubbed on the affected area. P2 has 2 % diclophenac and is applied to the affected area using a...read more
5 stars

RE:RE:RE:Sellers backing away?

C99 I commend you for your intuitive sense. Nothing makes complete sense here other than a full monetization of all assets prior to becoming an equity assemblage of Endo. WF10 is going to be a feral...read more
1 star

RE:RE:Sellers backing away?

Sales of Voltaren gel in the US are about $250 million. P2 is very close to Voltaren except a different application . That Nuvo is doing. phase III on P2 explicitly for the over the counter type of...read more
5 stars

RE:RE:Sellers backing away?

Why would Endo buy Nuvo for Pennsaid 2%? The fact they gave back the rights suggest reduced interest. If they were going to buy out Nuvo why would they let management re-sell the Pennsaid 2% rights...read more
3 stars

RE:Sellers backing away?

Voltaren, a topical NSAID of similar chemical composition as P2 has world wide sales in excess of $800 million US. it is available over the counter in certain countries P2 should be highly...read more
5 stars

Sellers backing away?

$6.85 trades at 1:03 with total volume at 241,000 shares. I did a quick tally on Level II and there were only 92,600 shares for sale between the current market price and $40 share suggesting to me...read more
4 stars

Transformative Event

Listening to the latest CC and talking to the individuals involved, there will be a transformative event in 2015. I always thought that it was Phase II results for WT10 and perhaps that remains so...read more
5 stars

Next Target Level

Now that Nuvo's share price has reached the target price of $6.60 to $6.80 based on the previous tecnical breakout where to next. Taking a look at the charts there appears to be a price gap between $7...read more
3.5 stars

RE:RE:Nuvo Research® reacquires Pennsaid® 2% rights

Interesting that management had to buy back something they got no value for in the first place. Is it possible they have already given up some WF10 rights to Paladin already?  rate and reply
1 star

RE:RE:RE:Nuvo Research® reacquires Pennsaid® 2% rights

pennsaid all over again.  :)  and what about the other drug that they had a research report on anticipating possible sales. cheers, dave.  rate and reply
5 stars

RE:RE:Nuvo Research® reacquires Pennsaid® 2% rights

overflowing wrote: Wow. Any theories as to what the non-cash consideration is?  Maybe Dan and John gave Paladin execs a tug under the table at their negotiation session!  rate and reply
3 stars

RE:Nuvo Research® reacquires Pennsaid® 2% rights

Another superb move by Nuvo. Fabrice has been spot on so far. Non-cash considerations ? Paladin ( Endo ) is a probable suitor, so one way or another, they will reacvquire these rights once Nuvo has...read more
0 stars

RE:Nuvo Research® reacquires Pennsaid® 2% rights

Wow. Any theories as to what the non-cash consideration is?  One wild guess: perhaps Nuvo gave Paladin the right to match any offer related to WF-10.  rate and reply
5 stars

Nuvo Research® reacquires Pennsaid® 2% rights

MISSISSAUGA, ON, Nov. 13, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced that it has...read more
3 stars

RE:Christmas article for the masses. Need2

Much as Fabby has stated, and to no ones surprise,management is proceeding full steam ahead with its asset monetization program. It truly does unlock the latent value in the best kind of way...hard...read more
3 stars

RE:Christmas article for the masses. Need2

Thanks for posting Need2 - that should bring in more buyers. We sure have had a nice run.  This has been a good year and the next few months look positive..been a long time since I could say that...read more
5 stars

Christmas article for the masses. Need2

Nuvo Research biotechnology stock has the potential for great reward FABRICE TAYLOR RTGAM Fabrice Taylor, CFA, publishes the President's Club investment letter. His letter and The Globe and Mail have...read more
5 stars

RE:NL analyst advocates to Add

Perhaps a upfront lump sum for some South America license .  rate and reply